These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6800432)

  • 21. Chemoprophylaxis of bladder cancer recurrence: immunological aspects.
    Corrado F; Lalanne G; Pizza GC
    Panminerva Med; 1974 Mar; 16(3):85-91. PubMed ID: 4217438
    [No Abstract]   [Full Text] [Related]  

  • 22. [Chemotherapy of bladder neoplasms--studies of preventive measures against recurrence of superficial bladder neoplasms].
    Okajima E; Motomiya Y; Ishuin M; Ikuma S; Ohara S
    Nihon Rinsho; 1977 May; 35(5):1987-91. PubMed ID: 407385
    [No Abstract]   [Full Text] [Related]  

  • 23. Intravesical chemotherapy: how effective is it?
    Heney NM
    Urology; 1988 Mar; 31(3 Suppl):17-9. PubMed ID: 3126591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical chemotherapy in a controlled trial with thio-tepa versus doxorubicin hydrochloride.
    Horn Y; Eidelman A; Walach N; Ilian M
    J Urol; 1981 May; 125(5):652-4. PubMed ID: 6785455
    [No Abstract]   [Full Text] [Related]  

  • 25. Severe pancytopenia associated with the use of intravesical thio-TEPA.
    Watkins WE; Kozak JA; Flanagan MJ
    J Urol; 1967 Oct; 98(4):470-1. PubMed ID: 4964489
    [No Abstract]   [Full Text] [Related]  

  • 26. Intravesical chemotherapy for superficial bladder cancer.
    Koontz WW
    Urology; 1984 Apr; 23(4 Suppl):79-81. PubMed ID: 6424298
    [No Abstract]   [Full Text] [Related]  

  • 27. Intractable bladder hemorrhage requiring cystectomy after use of intravesical thiotepa.
    Treible DP; Skinner D; Kasimain D; Friedman NB; Kern WH
    Urology; 1987 Dec; 30(6):568-70. PubMed ID: 3120389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid tumour recurrence following cessation of long-term treatment with intravesical thiotepa.
    Mukamel E; Servadio C
    Br J Urol; 1994 Jul; 74(1):44-6. PubMed ID: 8044529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Low-grade, low-stage transitional carcinoma of the bladder. Analysis of 147 cases].
    Escudero Barrilero A; Gutiérrez Sanz-Gadea C; Hernández Fernández C; Mateos Torres A; Maganto Pavón E; Mayayo Dehesa T
    Actas Urol Esp; 1985; 9(2):135-46. PubMed ID: 3925729
    [No Abstract]   [Full Text] [Related]  

  • 30. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
    Fisher HA
    Prog Clin Biol Res; 1989; 310():275-83. PubMed ID: 2505271
    [No Abstract]   [Full Text] [Related]  

  • 31. Instillation of thio-tepa (Tifosyl) in vesical papillomatosis.
    Edsmyr F; Boman J
    Acta Radiol Ther Phys Biol; 1970 Oct; 9(5):395-400. PubMed ID: 4990891
    [No Abstract]   [Full Text] [Related]  

  • 32. Nephrogenic adenoma in patients with transitional cell carcinoma of the bladder receiving intravesical thiotepa.
    Wood DP; Streem SB; Levin HS
    J Urol; 1988 Jan; 139(1):130-1. PubMed ID: 3121867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical-experience with thiotepa in the treatment of bladder cancer].
    Gallo FJ; Menéndez-Ondina L; Matallana A; Bonilla JA; Serrano E; Carballido JA; Mendoza A
    Actas Urol Esp; 1978; 2(5):237-40. PubMed ID: 103371
    [No Abstract]   [Full Text] [Related]  

  • 34. Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor.
    Hu KN; Kim A; Khan AS; Soroff H; Gonder M
    Cancer; 1985 Apr; 55(8):1654-8. PubMed ID: 3156664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of cystography in thio-tepa toxicity.
    Orlin I
    J Urol; 1972 Aug; 108(2):257-8. PubMed ID: 4625850
    [No Abstract]   [Full Text] [Related]  

  • 36. [Serious complications following topical administration of thio-tepa in a patient with bladder carcinoma].
    Kaczmarek A
    Wiad Lek; 1978 Apr; 31(8):547-50. PubMed ID: 96607
    [No Abstract]   [Full Text] [Related]  

  • 37. The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
    Hisazumi H; Uchibayashi T; Naito K; Misaki T; Miyazaki K
    J Urol; 1975 Sep; 114(3):394-8. PubMed ID: 806708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer.
    Seraphim LA; Perrapato SD; Slocum HK; Rustum YM; Huben RP
    J Urol; 1991 Mar; 145(3):613-7. PubMed ID: 1900087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors influencing the absorption of antineoplastic agents in intravesical instillation treatment of bladder tumors. An experimental and clinical study.
    Gu FL; Shi T; Feng T; Wu JP
    Chin Med J (Engl); 1987 Feb; 100(2):127-31. PubMed ID: 3109841
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
    Zincke H; Benson RC; Hilton JF; Taylor WF
    J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.